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Abstract
Cytokine expression patterns of T cells can be regulated by pre-commitment to stable effector phenotypes, further
modification of moderately stable phenotypes, and quantitative changes in cytokine production in response to acute
signals. We showed previously that the epidermal growth factor family member Amphiregulin is expressed by T cell
receptor-activated mouse CD4 T cells, particularly Th2 cells, and helps eliminate helminth infection. Here we report a
detailed analysis of the regulation of Amphiregulin expression by human T cell subsets. Signaling through the T cell
receptor induced Amphiregulin expression by most or all T cell subsets in human peripheral blood, including naive and
memory CD4 and CD8 T cells, Th1 and Th2 in vitro T cell lines, and subsets of memory CD4 T cells expressing several
different chemokine receptors and cytokines. In these different T cell types, Amphiregulin synthesis was inhibited by an
antagonist of protein kinase A, a downstream component of the cAMP signaling pathway, and enhanced by ligands that
increased cAMP or directly activated protein kinase A. Prostaglandin E2 and adenosine, natural ligands that stimulate
adenylyl cyclase activity, also enhanced Amphiregulin synthesis while reducing synthesis of most other cytokines. Thus, in
contrast to mouse T cells, Amphiregulin synthesis by human T cells is regulated more by acute signals than pre-
commitment of T cells to a particular cytokine pattern. This may be appropriate for a cytokine more involved in repair than
attack functions during most inflammatory responses.
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Introduction
Different functional subsets of CD4 T cells are crucially
involved in immune defense against diverse pathogens. At least
four effector subsets are derived by differentiation from naı ¨ve CD4
T cells, and each expresses a characteristic combination of
transcription factors, soluble mediators and surface molecules
[1,2]. Th1 cells predominantly produce interferon-c (IFNc) and
protect against intracellular pathogens; Th2 cells produce inter-
leukin (IL)-4, IL-5 and IL-13 and help to eliminate extracellular
parasites; Th17 cells produce IL-17a and IL-17f and are crucial in
fighting against extracellular bacteria and fungi; whereas induced
T regulatory cells (iTreg) produce IL-10 and Transforming
Growth Factor b (TGFb), and suppress T and B cell effector
responses.
Although the initial Th1 and Th2 subsets are relatively stable,
recent studies have demonstrated some flexibility and plasticity,
particularly in other CD4 T cell subsets. Cytokines and other
soluble mediators in the lymph node and inflamed tissue can
further affect the cytokine expression profile of effector CD4 T
cells [3], in some cases by changing the differentiation status of the
effector CD4 T cells. Primed precursor CD4 T (Thpp) cells, that
produce mainly IL-2 and chemokines when stimulated, remain
uncommitted with respect to their effector cytokine pattern and
can later differentiate into either Th1 or Th2 cells [4–6].
Suppressive Treg cells, expressing the forkhead transcription
factor Foxp3, can lose the expression of Foxp3 and acquire the
ability to produce pro-inflammatory cytokines during autoimmu-
nity [7]. Th17 cells can acquire the ability to produce IFNc in Th1
polarizing conditions [8,9]. Adoptively transferred IL-4-producing
Th2 effector cells can produce IFNc during viral challenge
infections [10]. Th9 cells develop from Th2 populations in the
presence of TGFb [11,12] and T follicular helper (Tfh) cells may
represent a further differentiation step from several of the other
subsets [13].
Acute modifications of cytokine patterns can also occur. IL-12+
IL-18 enhance the secretion of IFNc by Th1 cells [14,15], and IL-
2 enhances cytokine production [16,17]. In contrast, IL-10,
TGFb, prostaglandin E2 (PGE2) and adenosine inhibit inflam-
matory cytokine production [18–20].
Mouse Th2 cells, but not naive or Th1 cells, express
Amphiregulin (AR), a member of Epidermal Growth Factor
(EGF) family. Like other EGF members, AR is expressed as a
transmembrane precursor protein and released by proteolytic
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promotes proliferation and differentiation of epithelial cells,
fibroblasts and keratinocytes [23–25]. AR-deficient mice [26]
showed slower kinetics of clearance [27] of the helminth parasite,
Trichuris muris, that is cleared most effectively by Th2-biased
responses. AR production is also induced in human mast cells by
IgE cross-linking [28,29], in human eosinophils by IL-5 [30], and
in human basophils by IL-3 [31]. Thus AR is induced by
activation of at least four cell types contributing to Type
2 inflammation, suggesting a role for AR during an allergic
immune response. In addition, production of AR by immune cells
is potentially important for tissue remodeling and repair [21,26]
during and after damaging immune responses.
Very little is known about the regulation of AR gene expression
in human T cells. We examined the regulation of AR synthesis by
human T cells, and found that in contrast to mice, many subsets of
human T cells, including CD4 and CD8, naive and memory, Th1
and Th2, all express AR in response to TCR stimulation. Factors
that elevate cAMP levels synergized with TCR stimulation to
enhance AR expression, while inhibiting expression of most
inflammatory cytokines. Thus in human T cells, AR production is
regulated strongly by the environmental context during stimula-
tion, but not restricted to particular precommitted effector subsets
of T cells.
Materials and Methods
Antibodies and Reagents
Biotinylated goat anti-human AR and biotinylated goat normal
IgG (isotype control), and APC conjugated anti-human CCR4
(205410) were obtained from R&D Systems (Minneapolis, MN).
LEAF
TM purified anti-human CD3e (OKT3), APC-Cy7 conju-
gated anti-human CD4 (RPA-T4), Pacific Blue or APC-Cy7
conjugated anti-human CD69 (FN50), PE-Cy5 conjugated anti-
human CD154 (24–31), PerCP-Cy5.5 conjugated anti-human
CD27 (O323), Alexa Fluor 700 conjugated anti-human CD62L
(DREG-56), Pacific Blue conjugated anti-human CXCR3 (TG1/
CXCR3), PE-Cy7 or PE-Cy5 conjugated anti-human CD123
(6H6), Alexa Fluor 700 conjugated anti-human IL-2 (MQ1-
17H12), FITC conjugated anti-human IL-4 (MP4-25D2), and
PerCP-Cy5.5 conjugated anti-human IL-17A (BL168) were
purchased from BioLegend (San Diego, CA). Functional grade
purified anti-human CD28 (CD28.2), PE conjugated anti-human
CD45RA (HI100), FITC conjugated anti-human CD45RO
(UCHL1), PE-Cy5 conjugated anti-human CD19 (HIB19), PE-
Cy7 conjugated anti-human IFNc (4S.B3), and APC-conjugated
streptavidin were obtained from eBioscience (San Diego, CA).
Alexa Fluor 488 conjugated anti-human CXCR5 (RF8B2) and
PE-Cy7 conjugated anti-human CCR7 (3D12) were purchased
from BD Bioscience (San Jose, CA). QdotH 605 conjugated anti-
human CD3 (UCHT1), PE-Texas Red and QdotH 705 conjugated
anti-human CD8a (3B5), PE-Texas Red conjugated anti-human
CD4 (S3.5), TRI-COLOR and QdotH 800 conjugated anti-
human CD14 (Tu ¨K4), QdotH 655 conjugated anti-human
CD45RA (MEM-56), Pacific Blue conjugated anti-human TNFa
(MP9-20A4), and LIVE?DEAD Fixable Yellow Dead Cell Stain
Kit were obtained from Invitrogen (Carlsbad, CA).
7-Aminoactinomycin D (7-AAD) and TAPI-1 was obtained
from Calbiochem (Gibbstown, NJ). cAMP agonist (8-CPT-cAMP)
and cAMP antagonist (Rp-8-Br-cAMP) were purchased from
BioLog (Bremen, Germany). Phorbol 12-myristate 13-acetate
(PMA), ionomycin, monensin, PGE2, forskolin and 3-Isobutyl-1-
methylxanthine (IBMX), adenosine were obtained from Sigma
(St.Louis, MO).
Human Peripheral Blood T cell Isolation and Activation
Heparinized blood was obtained from healthy donors under a
protocol approved by the University of Rochester Medical Center
Research Subjects Review Board. Written, informed consent was
obtained from all subjects. PBMC were isolated by Ficoll-Hypaque
(Cellgro, Herndon, VA) density gradient centrifugation. Cells were
suspended in complete RPMI-8 (RPMI-1640 medium containing
100U penicillin/streptomycin (Invitrogen) supplemented with 8%
heat-inactivated fetal calf serum (FCS, HyClone, Logan, UT)). In
the experiment treating cells with adenosine, serum-free medium
X-VIVO
TM 20 (Lonza, Walkersville, MD) was used.
To purify human naı ¨ve and memory CD4 T cells from PBMC,
fresh PBMC were stained with antibodies specific for cell surface
markers and CD4+CD8-CD14-CD123-CD45RA+CD45RO-
(naı ¨ve CD4 T cells) and CD4+CD8-CD14-CD123-CD45RA-
CD45RO+ (memory CD4 T cells) were sorted on a FACSAria
(BD Bioscience, San Jose, CA).
In vitro Induction of Allogeneic Th1 and Th2 cell Lines
Purified human naı ¨ve CD4 T cells were stimulated with
irradiated (100Gy) allogeneic Epstein-Barr virus (EBV) – trans-
formed B cells (1:1 ratio) in complete RPMI-8 medium at
10
5 cells/mL in round-bottom 96-well plate. Th1-biased cultures
contained recombinant human IL-2 (5 ng/mL, PeproTech),
recombinant human IL-12 (20 ng/mL, PeproTech) and anti-IL-
4( 5 mg/ml, R&D Systems). Th2-biased cultures contained
recombinant human IL-2 (5 ng/mL), recombinant human IL-4
(20 ng/mL, R&D Systems), anti-IL-12 (5 mg/ml, ebioscience) and
anti-IFNc (5 mg/ml, R&D Systems). Fresh medium containing
5 ng/mL IL-2 was added if necessary to cultures showing strong
proliferation. The cultures were restimulated and expanded every
seven days.
To enrich for cells with the Th1 or Th2 phenotypes, after
14 days priming, Th1 and Th2 cells were stimulated with plate-
bound anti-CD3+ anti-CD28 for 8 hours. IFNc+ Th1 cells and
IL-5+ Th2 cells were stained and sorted by the MACS cytokine
secretion assay (Miltenyi Biotec, Auburn, CA) according to the
manufacturer’s instructions. The enriched IFNc+ Th1 cells and
IL-5+ Th2 cells were expanded as previously for 14 days.
Intracellular Staining and Cell Surface Staining
For intracellular staining (ICS) of AR, PBMC (10
6 per well)
were stimulated with medium alone, anti-CD3 (5 mg/ml) + anti-
CD28 (1 mg/ml), Staphylococcal enterotoxin B (SEB, 1 mg/ml),
PMA (10 ng/mL) + ionomycin (500 ng/mL), influenza H1N1
peptides (H1N1 [New Caledonia/New York], 20 ng/mL/pep-
tide), Fel d1 (50 mg/mL, INDOOR, Charlottesville, VA), Der p1
(50 mg/mL, INDOOR) or Tetanus peptides (3 mg/mL/peptide) in
round-bottom 96-well plate (Costar, Corning Inc., Corning, NY).
Th1 or Th2 cultures were treated with medium alone or PMA +
ionomycin. After 10 hours stimulation (with 2 mM monensin
present for the last 8 hours), the cells were first stained with
LIVE?DEAD Fixable Yellow Dead Cell Stain Kit, and then
stained for cell surface markers CD4, CD8, CD14, CD123, and
CD45RA. After cells were fixed and permeabilized using Fix-Perm
(BD Bioscience), the cells were stained with anti-AR, anti-IFNc,
anti-IL-2, anti-IL-4, anti-IL-17A, anti-TNFa, anti-CD3 and anti-
CD69 (or anti-CD154) intracellularly.
For cell surface staining of AR, PBMC were stimulated with
medium alone or 1 mg/ml SEB in the presence or absence of
50 mM TAPI-1, an ADAM17 protease inhibitor [32], for 6, 12,
and 24 hours. After stimulation, the cells were stained with
antibodies against AR, CD3, CD4, CD8, CD14, CD123, CD69
and 7-AAD. Data were acquired using an LSR II flow cytometer
Acute Not Pre-Committed T Cell Cytokine Regulation
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Inc., Ashland, OR).
Quantitative Real Time PCR for Gene Expression
Total RNA was extracted using TRIzol (Invitrogen) according
to the manufacturer’s instructions. cDNA was prepared by reverse
transcription from total RNA using MultiScribe
TM Reverse
Transcriptase (Applied Biosystems, Foster City, CA) with random
hexamer primers (Applied Biosystems). Quantitative real-time
PCR (RT-PCR) was performed using the Applied Biosystems
7900HT Sequence Detection System. Primers and probes specific
for AR, Heparin-binding EGF-like Growth Factor (HB-EGF), IL-
2, IFNc, IL-3, IL-4, IL-5, IL-10, IL-13, CD3d, EGF, Neuregulin
(NRG) 1–4, epiregulin (EREG), betacellulin (BTC) and TGFa
were all obtained from TaqMan Gene Expression Assays (Applied
Biosystems). CD3d gene expression was used as an endogenous
control for normalizing mRNA amounts. All samples were run in
duplicate and data were analyzed using SDS software (Applied
Biosystems).
Measurement of AR Release
Purified CD4 T cells were treated with medium alone or CD3/
CD28 beads (cells:beads 2:1) in the presence or absence of 50 mM
TAPI-1. After 24 hours, the supernatants were collected and AR
was measured using the human Amphiregulin DuoSet ELISA
Development kit (R&D Systems). The detection limit of the assay
was 7.8 pg/mL. Because the antiserum for the ELISA was
produced by immunization with bacterial recombinant human
AR, and the standard is also non-glycosylated AR, this ELISA
probably underestimates the concentration of normal human
glycosylated AR.
Results
1. T cell Activation Induces Rapid AR Expression by
Human T Cells
Mouse Th2 cells produce AR in response to TCR-mediated
activation [27], and the expression of AR by hemopoietic cells
contributes to the clearance of a helminth parasite. However, our
recent studies showed that basophils were the major human
PBMC type that produced AR in response to anti-CD3/CD28
stimulation [31], whereas production of AR by T cells was much
lower. Therefore we examined human T cells in more detail, to
determine whether human T cells could produce AR, and if so,
whether this was produced preferentially by human Th2 cells.
Human PBMCs were stimulated with soluble anti-CD3+ anti-
CD28, SEB, or PMA + ionomycin for 10 hours (protein secretion
inhibitors were added during the last 8 hours). CD69 staining
increased on almost all anti-CD3/CD28- and P+I-stimulated cells,
and a subset of SEB-stimulated cells (Figure 1A). AR staining was
increased, only in the CD69+ population, and this increase was
most obvious in the P+I-stimulated cells. For all three stimulation
conditions, the staining intensity for AR increased for the whole
CD69+ population, i.e. separate positive and negative populations
were not resolved, and so the percentage of cells in the AR+ gate
may be an underestimate of the total number of cells expressing
AR. The specificity of AR staining was demonstrated by using a
control goat antiserum (right column). Similar results were
obtained with CD8 T cells (Figure 1A).
To independently confirm AR expression by human T cells,
and to test whether T cells produced AR as a direct result of TCR
stimulation, human CD4 and CD8 T cells were purified by
sorting, and stimulated with beads coated with anti-CD3+ anti-
CD28 antibodies. At different times, RNA was extracted from the
cells, and levels of AR and IL-2 mRNA measured by RT-PCR.
AR mRNA levels increased rapidly after stimulation, and returned
to low levels after ten hours, whereas IL-2 showed slower kinetics
(Figure 1B). The kinetics of AR production were similar in CD4
and CD8 T cells. Thus human T cells directly express AR in
response to polyclonal TCR stimulation.
2. Expression of Other EGF Family Members by Human T
Cells
As demonstrated by other studies [33], HB-EGF mRNA was
also upregulated in activated human CD4 T cells (Figure 2A),
although the levels were lower than AR and peaked at a later time
(Figure 2B). TGFa and EREG mRNA were also detected in
resting CD4 T cells, but not increased during TCR activation.
Other EGF members were undetectable. In our previous mouse
experiments [27], AR and HB-EGF were also the only EGF family
members induced by TCR stimulation (data not shown).
Expression of HB-EGF protein was confirmed by cell surface
and intracellular staining (data not shown).
3. Kinetics of AR Surface Expression and Release
EGF family members (including AR) are initially expressed as
transmembrane proteins and released into the extracellular region
after cleavage by metalloproteases, particularly ADAM17 [22]. To
determine whether T cells also initially expressed surface AR and
then released the soluble cleavage product, surface AR was stained
during TCR activation in the presence or absence of the
ADAM17/TACE inhibitor TAPI-1 [32]. TAPI-1 increased AR
expression on the surface of both CD4 and CD8 T cells measured
by frequency (Figure 3A) or fluorescence intensity (data not
shown). Conversely, TAPI-1 decreased soluble AR in the
supernatant (Figure 3B). In the absence of TAPI-1, AR expression
on T cells gradually decreased and was barely detectable after
24 hours. As ADAM17 mRNA was detected by RT-PCR in
resting human T cells and upregulated on activation (data not
shown), these results suggested that AR was first synthesized as a
membrane protein on human T cells and then released by
ADAM17 cleavage, as in other cell types [34,35].
4. Most or all T Cell Subsets can Express AR
In mice, AR was expressed selectively in TCR-activated Th2
cells [27] but not Th1 (Figure S1) or naive CD4 T cells. This was a
pre-committed, intrinsic property of the Th2 cells, as Th2 but not
Th1 cells expressed AR even when in vitro-derived mouse Th1 and
Th2 cell lines were activated together in the same culture (data not
shown). However, most human CD4 (and CD8) T cells expressed
AR in response to PMA plus ionomycin stimulation (Figure 1A).
We therefore examined in more detail which human T cell subsets
were responsible for AR production.
Naive and memory CD4 and CD8 T cells produce
AR. To examine the ability of naive and memory T cell
subpopulations to express AR, we stimulated PBMC with an
allogeneic EBV-transformed B cell line, which would be expected
to activate a small fraction of both memory and naive CD4 and
CD8 T cells. Alloantigens stimulated a fraction of both CD4 and
CD8 T cells to produce AR (Figure 4A), relative to the
unstimulated control. The specificity of staining was confirmed
by isotype control antibodies. The cells producing AR (and other
cytokines) were included in the CD69+ population.
AR was induced by allogeneic stimulation in both CD45RA-
and CD45RA+ subsets of CD4 and CD8 T cells at frequencies
ranging from 0.028% to 0.35%. These levels were comparable to
the frequencies of CD4+ CD45RA+ or CD45RA- T cells
Acute Not Pre-Committed T Cell Cytokine Regulation
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IFNc. As expected, IL-2 was produced by both memory
(CD45RA-) and naive (CD45RA+) CD4 T cells, whereas IFNc
(and IL-4 at low levels) were produced mainly by memory cells
(Figure 4B).
The expression of AR by both CD45RA- and CD45RA+
subsets of CD4 T cells was tested at the mRNA level in SEB-
stimulated cells sorted according to AR and CD45RA expression
(Figure 4C). Confirming the specificity of the anti-AR antibody
Figure 1. TCR activation induced AR expression in human PBMC T cells. (A) PBMC were treated as indicated and analyzed by ICS. The upper
panels show the gating strategy to identify activated (CD69+) CD4 or CD8 T cells expressing AR. The lower panels show the induction of AR by
different stimuli in CD4 or CD8 T cells. (B) AR and IL-2 mRNA were measured by RT-PCR in purified CD4 and CD8 T cells after activation by anti-
CD3+anti-CD28 beads. Results in (A) and (B) are representative of at least three experiments.
doi:10.1371/journal.pone.0039072.g001
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CD45RA- or CD45RA+ populations.
AR is produced by memory CD4 T cell subsets expressing
different cytokine phenotypes. Although naive CD4 T cells
are relatively homogeneous, the memory population includes a
wide range of differentiated effector subsets. As AR is expressed
selectively by mouse Th2 cells, we examined whether AR
production by human CD4 memory T cells was preferentially
associated with expression of a particular cytokine or surface
marker pattern. Th1- and Th2-biased human CD4 T cell
populations were induced by stimulation of sorted naive human
CD4 T cells with an allogeneic B cell line in Th1- or Th2-biasing
cytokine conditions. The populations were further enriched by
using the Cytokine Secretion Assay to sort IFNc- or IL-5-
producing cells, respectively. The resulting populations were
strongly polarized, but unlike mouse T cells, both Th1 and Th2
human cell lines expressed AR (Figure 5A).
These results were confirmed using ex vivo human CD4 T cell
populations. Human PBMC were stimulated with SEB, and AR
and other cytokines measured by intracellular staining. Naive cells
(CD45RA+) expressed high levels of IL-2 and AR, but very low
levels of either IFNc or IL-4 (data not shown). Memory cells
produced all cytokines tested, at varying frequencies. To
determine whether AR expression was associated positively or
negatively with subset-specific cytokines, the frequencies of cells
expressing AR plus each of the other cytokines were measured
from the ICS results. These values were then compared with the
double-producing frequencies predicted for random association of
each cytokine pair, by multiplying the individual frequencies for
each cytokine. Figure 5B shows that AR was expressed in
association with TNFa, IL-2, IFNc, IL-4 and IL-17 at slightly
higher frequencies than predicted by random association. Simi-
larly, TNFa and IL-2 showed positive associations with all other
cytokines. In contrast, the subset-specific cytokines IFNc, IL-4 and
Figure 2. HB-EGF was also expressed by TCR activated human CD4 T cells. (A) Purified CD4 T cells were incubated with medium alone or
anti-CD3/CD28 beads. At 4 hours, the mRNA levels of EGF family members were measured by RT-PCR. * Indicates undetectable values. (B) The
kinetics of HB-EGF mRNA expression were measured on purified CD4 T cells responding to anti-CD3/CD28 beads. All results are representative of
three independent experiments.
doi:10.1371/journal.pone.0039072.g002
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expected. These results were confirmed at the RNA level by
sorting SEB-stimulated human PBMC according to surface AR
expression. Both AR+ and AR- memory CD4 T cell populations
expressed similar levels of IL-4 and IFNc as measured by RT-
PCR (Figure 5C). IL-2 mRNA levels were higher in AR+ T cells,
in both CD45RA- and CD45RA+ cells.
AR is produced in response to antigen stimulation. We
next tested whether human CD4 T cells expressed AR during
antigen/APC stimulation in response to influenza peptides,
allergens or tetanus antigens to stimulate Type 1, Type 2 and
Figure 3. Release of AR from the T cell surface was blocked by the ADAM17 inhibitor TAPI-1. (A) PBMC were stimulated with SEB in the
presence or absence of TAPI-1 for variable times. After cell surface staining of AR, the percentage of CD69+AR+ cells within CD4 and CD8 T cells was
analyzed. (B) Purified CD4 T cells were treated with medium alone or anti-CD3/CD28 beads with or without TAPI-1 for 24 hours. The concentration of
AR in the supernatant was measured by ELISA. All results are representative of at least three experiments.
doi:10.1371/journal.pone.0039072.g003
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stimulated with antigens for 10 hours, and AR and other cytokines
measured by ICS.
Although these three antigens induced in vivo recall responses
with characteristically different levels of IL-2, IFNc and IL-4, all
three antigens induced substantial production of AR in the
activated (CD154+) cells (Figure 5D). Similar results were obtained
with cells from multiple subjects, although the magnitudes of the
antigen responses were variable for all cytokines. Thus AR can be
expressed by all the conventional defined subsets of T cells that we
have tested, including CD4 and CD8, naı ¨ve and memory, Thpp,
Th1 and Th2.
To confirm the protein results, influenza-specific CD69+ IFNc+
cells were sorted from two subjects (results from one subject are
shown in Figure 5E), and RT-PCR demonstrated that AR mRNA
levels were strongly elevated in the IFNc+ influenza-specific cells
Figure 4. Both naı ¨ve and memory human CD4 T cells expressed AR during TCR activation. (A) PBMC were treated with medium alone or
allogeneic EBV-transformed B cells for 10 hours and analyzed by ICS. The gating strategy to identify activated CD4+ and CD8+ T cells is shown. (B) AR,
IL-2, IFNc or IL-4 expression was measured in four subjects in CD45RA+ (open) and CD45RA- (solid) CD4+ and CD8+ T cells after allogeneic EBV-
transformed B cell stimulation. Background values have been subtracted. (C) PBMC were treated with medium alone or SEB in the presence of TAPI-1
for 8 hours. Then six populations were sorted based on surface AR, CD69 and CD45RA expression (left). AR mRNA in each population was measured
by RT-PCR (right). Results in (A) and (B) represent at least three experiments, (C) represents two experiments.
doi:10.1371/journal.pone.0039072.g004
Acute Not Pre-Committed T Cell Cytokine Regulation
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orCD69+IFNc-cellsfromstimulatedcultures.Thespecificityofthe
sortingwasdemonstrated bythestrongenrichmentofIFNcmRNA
in the CD69+ IFNc+ population (Figure 5E).
AR is produced by T cell subsets expressing different
chemokine receptors and surface markers. Chemokine
receptors expressed selectively by T cell subsets lead to different
homing and chemotactic properties. Expression patterns of
chemokine receptors are partly but not entirely related to cytokine
commitment patterns [36–39]. Additional surface markers, includ-
ing CD27 and the homing receptor CD62L are also expressed
heterogeneously on human CD4 T cells. We therefore examined
ARexpressionwithinsubsetsofmemoryCD4Tcellsdefinedbythe
expression of these proteins. AR was produced at approximately
similar frequencies by CD4 T cells positive or negative for the
chemokine receptors CCR4, CCR7, CXCR3 and CXCR5, as well
as CD62L and CD27 (Figure 6). However, expression of the
activation-induced protein CD69 was strongly correlated with AR
expression, asseeninpreviousfigures.Takentogetherwiththedata
described above, AR expression appears to be a general ability of
most or all subtypes of human T cells after TCR activation.
5. Signaling through the cAMP/PKA Pathway Synergizes
with TCR Signals to Induce AR
As our results had demonstrated that AR production was not
limited to a pre-committed subset of T cells, we then tested
whether AR production was regulated by acute signals in the
immediate milieu during TCR stimulation. In many cell types AR
is strongly regulated by the cAMP-PKA-CREB signaling pathway.
AR expression was significantly up-regulated by cAMP-elevating
agents in both resting and anti-CD3 stimulated human PBMC
populations enriched for human T cells [40]. However, in that
study the negatively-selected T cell population would also have
contained basophils, and we have shown that basophils express
AR rapidly in response to IL-3 and cAMP agonist ([31] and
unpublished data). Thus anti-CD3 stimulation of the CD4 T cell +
basophil population could have induced IL-3 production by T
cells, indirectly resulting in AR production by basophils. We have
now re-examined the effect of cAMP elevation on the expression
of AR by different T cell subsets.
TCR and cAMP signals synergize to induce AR
expression. TCR activation alone (which transiently elevates
cAMP [41]) induced transient AR mRNA expression (Figure 7A),
and a strong cAMP agonist (PKA activator 8-CPT-cAMP) also
induced low levels of AR in the absence of other signals. However,
TCR and PKA signaling synergized to induce higher and more
sustained levels of AR and HB-EGF mRNA (Figure 7A), as well as
high levels of AR protein (supernatant plus cell-associated,
Figure 7B). This strong synergy contrasts with a previous study
[40], possibly due to the presence of basophils in the responding
population in that study.
As both naive and memory CD4 T cells produce AR (Figure 4),
we tested whether PKA activation would enhance AR expression
in both populations. Figure 7C shows the response of purified
Figure 5. Several human CD4 T cell subsets can produce AR. (A) Allogeneic Th1 and Th2 cell lines from three subjects were stimulated with
PMA + ionomycin for 6 hours. The percentage of cells expressing IFNc, IL-4, and AR was analyzed by ICS. (B) The expression of AR and other cytokines
was measured in SEB-stimulated PBMC from four subjects by ICS, calculating the frequencies of single cytokine producers, and all possible
combinations of double-producers, among the CD154+ CD4+ T cells. The figure shows the ratio between the observed frequencies of double-
producing T cells for each cytokine pair, and the expected frequencies (calculated as the product of the individual frequencies for each cytokine).
Values represent the ratios for the double-producer combination defined by the row and column labels. Ratios above or below 1 are indicated by
solid or open symbols, respectively. (C) IL-4, IFNc and IL-2 mRNA levels were measured by RT-PCR in the sorted populations described in Figure 4C.
(D) PBMC were treated with influenza H1N1 peptides or tetanus (five subjects each), or the allergens Fel d1 (solid symbols) or Der p1 (open
symbols)(three subjects each). The numbers of memory CD4 T cells expressing AR and other cytokines were measured by ICS. The backgrounds (no
antigen) have been subtracted. Each symbol represents one individual and the filled bar is the mean of all tested subjects. (E) CD69+ CD4+ T cells
(Control_CD69+) were sorted from PBMC incubated in medium alone. CD69+IFNc+ and CD69+IFNc- CD4 T cells were sorted from influenza peptide-
treated PBMC using the cytokine secretion assay. The mRNA levels of IFNc and AR were measured by RT-PCR. Results in (A-C) are representative of at
least three experiments, (D) represents two experiments using a total of 5 independent subjects, and (E) represents two experiments.
doi:10.1371/journal.pone.0039072.g005
Figure 6. AR is produced by T cell subsets expressing different chemokine receptors and surface markers. PBMC were treated with
medium alone, anti-CD3+ anti-CD28 antibodies, or SEB in the presence of TAPI-1 for 8 hours. Cells were stained for AR and cell-surface markers and
analyzed by flow cytometry. Representative of two experiments.
doi:10.1371/journal.pone.0039072.g006
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e39072CD45RA+ and CD45RA- CD4 T cells to anti-CD3/CD28
stimulation. The cAMP agonist strongly enhanced AR expression
in both populations, with a slightly higher optimal concentration
in naive CD4 T cells (30 mM) compared to memory CD4 T cells
(10mM).
AR expression is modified by natural and synthetic
modulators of cAMP signaling. In the experiments described
above, cAMP signaling was altered by an agonist (8-CPT-cAMP)
that directly targeted PKA to mimic the increase of intracellular
cAMP levels. To further confirm that the cAMP-PKA-CREB
signaling pathway regulates AR expression, we tested natural and
pharmacological agents that increase the intracellular levels of
cAMP by acting at two additional steps: PGE2 and adenosine are
natural ligands for G-protein coupled receptors that activate
adenylyl cyclase [20,42–44]; forskolin activates adenylyl cyclase
directly [20]; and IBMX is a broad inhibitor of cAMP-degrading
phosphodiesterases [45].
Consistently, all four cAMP elevating agents upregulated AR
mRNA and protein expression in anti-CD3-stimulated T cells. In
each case, the elevated signal was blocked by the cAMP antagonist
(Figure 7D). The enhancement of AR by the PDE inhibitor
suggested that PDE reduced the moderate levels of cAMP induced
by TCR activation in CD4 T cells [41].
AR and other cytokines are regulated reciprocally by
cAMP signals. In contrast to the enhancement of AR
expression, the cAMP agonist inhibited expression of many other
cytokines (Figure 7E), and all four PKA-activating agents
described in Figure 7 inhibited expression of IL-2 and IFNc (data
not shown). These results are consistent with previous studies with
cAMP agonists and natural cAMP elevating agents, such as PGE2
and adenosine [19,20]. Thus AR expression in T cells is enhanced
under conditions that suppress the production of many other
cytokines.
Discussion
In contrast to the preferential expression of AR by mouse Th2
cells, we have now shown that synthesis of human AR is not
restricted to a particular human T cell subset. AR can be produced
by activated naive and memory CD4 and CD8 T cells, including
Th1 and Th2 phenotypes. Our results suggest that AR is not a
specific product of certain pre-committed effector subsets of
human CD4 T cells, but instead is regulated mainly by additional
signals present during T cell activation, particularly signals
influencing the cAMP signaling pathway. The lack of precommit-
ment suggests that, in contrast to the memory of effector functions
carried by T cells committed to Th1, Th2, Th17 etc phenotypes,
the amount of AR produced in a particular immune response is
regulated by the local environment during that response, but is less
influenced by previous immune priming. The discrepancy we have
identified between mouse and human T cell regulation highlights
the importance of performing cross-species comparisons of effector
T cell phenotypes.
AR production was not restricted to a defined T cell effector
subset, but AR and IL-2 levels were moderately correlated in both
naı ¨ve and memory CD4 T cells. Although this could indicate the
existence of a previously-unrecognized subset, it is possible that the
correlation could be the result of shared transcriptional or mRNA
stability regulatory factors, or to similar activation thresholds for
IL-2 and AR. Expression of AR also showed moderate correlation
with the expression of TNFa.
High levels of AR mRNA and protein were induced by synergy
between TCR signals and signals that elevated cAMP or activated
PKA. This contrasts with a previous report suggesting that both
resting and anti-CD3 stimulated T cells significantly up-regulated
AR in response to a cAMP agonist [40]. However, the enriched T
cell population used in that study was purified by negative
selection and very likely included basophils, which we have shown
are potent producers of AR in response to IL-3 [31]. AR
expression is also strongly enhanced by cAMP agonists in
basophils (Y. Qi and T.R. Mosmann, unpublished data) and so
it is possible that basophils may have produced the AR in response
to the cAMP agonist without TCR stimulation.
In contrast to the induction of AR by cAMP elevating agents,
these mediators suppress inflammatory responses by inhibiting
cytokine expression and T cell proliferation. Synthesis of several
pro-inflammatory or Type 1 cytokines is inhibited by cAMP
(Figure 7E and [19,20,46,47], whereas cAMP can either inhibit or
enhance production of Type 2 cytokines such as IL-4, IL-5 and
IL-13 (Figure 7E and [47]) depending on the stimulation
conditions [48,49].
Natural mediators that elevate the cAMP pathway and lead to
PKA activation include PGE2 (mainly via the G protein-coupled
receptors E2 and E4 on T cells) and adenosine (mainly via the A2A
receptor on T cells). Both mediators are produced at sites of
immune inflammation, adenosine by degradation of ATP from
dying cells, and PGE2 by activated macrophages. PKA activation
signals also synergized with TCR signals to induce HB-EGF
mRNA and protein expression in human CD4 T cells (data not
shown). Thus during the progression of an inflammatory response,
there may be a switch from pro-inflammatory cytokine production
to AR (and HB–EGF) production.
Our findings allow us to construct a model of the role of T cell
derived AR in adaptive immunity. During an immune response,
initial immune attack mechanisms that destroy the pathogen are
superseded at later times by suppression that reduces immunopa-
thology, and tissue repair that restores normal structure and
function. T lymphocytes are major cellular contributors to all three
phases, and are thought to play a role in repair by producing HB–
EGF and bFGF [33]. AR and HB–EGF, as members of the EGF
family, promote the proliferation of fibroblasts, epithelial cells, and
smooth muscle cells, which are major cell types repaired or
remodeled at local tissue sites during an inflammatory response.
Tissues with chronic inflammation show extensive cell prolifera-
tion, tissue thickening and reduced elasticity. Regulation of the
balance between attack and repair cytokines produced by T cells is
thus crucial to the successful outcome of the response.
Figure 7. TCR and cAMP synergize to induce AR production in human CD4 T cells. Purified CD4 T cells were incubated with or without TCR
stimulation (anti-CD3/CD28 beads) and the cAMP agonist. (A) AR and HB-EGF mRNA expression was measured by RT-PCR. (B) The concentrations of
AR in the supernatant and cell lysates were measured by ELISA. (C) Enriched CD45RA+CD45RO- (naı ¨ve) and CD45RA-CD45RO+ (memory) CD4 T cells
were treated with medium alone, or anti-CD3/CD28 beads in the presence or absence of cAMP agonist (1 , 1000 mM). The concentration of AR in the
supernatant at 24 hours was measured by ELISA. (D) Purified CD4 T cells were treated with medium alone, or anti-CD3/CD28 beads in the presence or
absence of the cAMP-modifying agents shown. RNA was extracted at 4 hours, and AR mRNA was measured by RT-PCR. The concentration of AR in
the 24-hour supernatant was measured by ELISA. (E) PBMC were treated with anti-CD3+ anti-CD28 antibodies in the presence or absence of cAMP
agonist or antagonist for 8 hours. CD4 T cells were purified by cell sorting and RNA was extracted. The mRNA levels of AR and other cytokines were
measured by RT-PCR. All results are representative of at least three experiments.
doi:10.1371/journal.pone.0039072.g007
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PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e39072In this model, AR derived from human T cells would be
expressed mainly in response to tissue injury, consistent with the
importance of the local environmental signals for AR regulation.
This contrasts with the requirement for specific effector mecha-
nisms to combat different pathogens, in which pre-commitment to
cytokine effector phenotypes (thus linking antigen and effector
specificities) may be more effective for regulating clearance
functions. Collectively, the coordinate inhibition of pro-inflamma-
tory cytokines and induction of tissue-remodeling cytokines of the
EGF family may represent a switch from pathogen clearance to
tissue repair mechanisms by effector human T cells.
Supporting Information
Figure S1 Mouse Th2 but not Th1 cells express AR in
response to TCR activation. In vitro induced allogeneic Th1
and Th2 cell lines [50] from B6PL or AR
2/2 mice were
stimulated with plate-coated anti-CD3 (2 mg/mL) + anti-CD28
(1 mg/mL) antibodies for 6 hours. Expression of AR, IFNc and
IL-4 in CD4 T cells was analyzed by ICS. Biotinylated goat anti-
mouse AR antibodies were obtained from R&D Systems. LEAF
TM
purified anti-mouse CD3e (145-2C11) and LEAF
TM purified anti-
mouse CD28 (37.51) were purchased from BioLegend. APC-Cy7
conjugated anti-mouse CD3 (17A2), Alexa Fluor 700 conjugated
anti-mouse CD4 (GK1.5), Pacific Blue conjugated anti-mouse
CD44 (IM7), PerCP-Cy5.5 conjugated anti-mouse CD69
(H1.2F3), APC conjugated anti-mouse IL-2 (JES6-5H4), PE-Cy7
conjugated anti-mouse IL-4 (BVD6-24G2), PE conjugated anti-
mouse IL-5 (TRFK5), and FITC-conjugated streptavidin were
obtained from eBioscience. PE-Alexa Fluor 610 conjugated anti-
mouse IFNc (XMG1.2) was obtained from Invitrogen. Similar
results were obtained in at least three experiments.
(TIF)
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